Evidence mapPaperPMID 42380331Full record

ArticleNature biomedical engineering2026

Derivation of functional retinal endothelial cells from human pluripotent stem cells for therapeutics and modelling.

Ying-Yu Lin, Parker Esswein, Lucas Ramirez, Emily Warren, Julian Nicenboim, Sharon Gerecht

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ying-Yu Lin *Department of Biomedical Engineering, Duke University, Durham, NC, USA.
Parker Esswein *Department of Biomedical Engineering, Duke University, Durham, NC, USA.ORCID http://orcid.org/0009-0003-4856-2539
Lucas RamirezDepartment of Biomedical Engineering, Duke University, Durham, NC, USA.
Emily WarrenDepartment of Biomedical Engineering, Duke University, Durham, NC, USA.ORCID http://orcid.org/0000-0001-5839-0222
Julian NicenboimDepartment of Biomedical Engineering, Duke University, Durham, NC, USA.
Sharon GerechtDepartment of Biomedical Engineering, Duke University, Durham, NC, USA. sharon.gerecht@duke.edu.ORCID http://orcid.org/0000-0002-8542-4835

Funding

National Aeronautics and Space Administration (NASA) TRISH-SNT0101National Science Foundation (NSF) GRFPU.S. Department of Defense (United States Department of Defense) NDSEGU.S. Department of Health & Human Services | NIH | National Eye Institute (NEI) EY035853
6 · The paper itself

Abstract

Retinal microvascular diseases involve a compromised inner blood-retina barrier (iBRB), which remains poorly understood. A renewable source of human iBRB endothelium is thus vital for advancing eye research and treatment development. Here we differentiated human induced pluripotent stem cells into retinal endothelial cells (iRECs) via the Wnt-β-catenin pathway, namely Norrin-Frizzled4 signalling. These iRECs show genetic, protein and functional fidelity as well as unique retinal features. When injected into oxygen-induced retinopathy mice, iRECs integrated into the host vascular network and revascularized the ischaemic eye, rescuing the tissue. In microphysiological models, iRECs form perfusable microvascular networks that recapitulate iBRB morphology and phenotype in both healthy and diabetic states while also physiologically organizing and interacting with induced pluripotent stem cell-derived retinal pericytes. Our study establishes functional human iRECs and microphysiological iBRB models that facilitate mechanistic studies aimed at identifying therapeutic targets and promoting the revascularization of injured retinas, thereby supporting treatment advancement.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.